Trial reportCancer discovery2021
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Open access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 1 pooled it
14.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.
- Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.International journal of biological sciences · 2022Pooled it
- Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.International journal of cancer · 2026Trial
- Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study.Cell reports. Medicine · 2024Trial
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.Cancer medicine · 2023Trial
- Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.Nature reviews. Clinical oncology · 2026Review
- HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer.Breast cancer research and treatment · 2026Article
- SpaCEy links spatial tissue patterns to clinical outcomes using explainable graph neural networks.Nature communications · 2026Article
- Article
- HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects.Science China. Life sciences · 2026Review
- Spatial habitat radiomics predicts tertiary lymphoid structure status and identifies an IDO1Journal for immunotherapy of cancer · 2026Article
- Article
- HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies.Cancer discovery · 2026Article
- SPP1-positive macrophages drive trastuzumab resistance in HER2-positive breast cancer.Cell communication and signaling : CCS · 2026Article
- Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.BMC cancer · 2026Observational
- PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- HER2∆16 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer.Nature communications · 2026Article
- Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response.Nature biomedical engineering · 2026Article
- Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity.Molecular oncology · 2026Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byHeterogeneous2021
Authors and funding
20 authors at 10 institutions in 2 countries.
Otto Metzger Filho *Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.
Giuseppe Viale *Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.
Shayna Stein *Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lorenzo TrippaData Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Denise A YardleySarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee.
Ingrid A MayerVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Vandana G AbramsonVanderbilt-Ingram Cancer Center, Nashville, Tennessee.ORCID 0000-0002-6855-1322
Carlos L ArteagaUT Southwestern Simmons Cancer Center, Dallas, Texas.
Laura M SpringMassachusetts General Hospital, Boston, Massachusetts.
Adrienne G WaksMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5649-7229
Eileen WrabelMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Michelle K DeMeoMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Aditya BardiaMassachusetts General Hospital, Boston, Massachusetts.
Patrizia Dell'OrtoDivision of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.ORCID 0000-0001-9166-0829
Leila RussoDivision of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.
Tari A KingBreast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
Kornelia PolyakMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5964-0382
Franziska MichorData Science, Dana-Farber Cancer Institute, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.
Eric P WinerMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8819-1723
Ian E KropMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.ORCID 0000-0002-6380-5944
Dana-Farber Cancer Institute · USEuropean Institute of Oncology · ITHarvard University · USMassachusetts General Hospital · USVanderbilt University · USBrigham and Women's Hospital · USBroad Institute · USTennessee Oncology · USThe University of Texas Southwestern Medical Center · USUniversity of Milan · IT
Funding
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MTargeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4MProject 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer TherapyU54CA193461 · NCI · DANA-FARBER CANCER INST · PI MICHOR, FRANZISKA · 2015 to 2020
$11.2MUnderstanding the Impact of Microscale and Nanoscale Heterogeneity and ResistanceU54CA209988 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GRAY, JOE W. · 2017 to 2021
$10.3MIntratumor heterogeneity underlying treatment resistance in HER2+ breast tumorsU01CA195469 · NCI · DANA-FARBER CANCER INST · PI GRAY, JOE W., MICHOR, FRANZISKA · 2015 to 2019
$3.3MIntratumor heterogeneity and therapeutic resistanceK99CA201606 · NCI · DANA-FARBER CANCER INST · PI JANISZEWSKA, MICHALINA · 2016 to 2017
$252kRational Design of Combination Therapy Administration Schedules Using Mathematical ModelingF31CA239565 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI STEIN, SHAYNA RENEE · 2019 to 2020
$57kNCI NIH HHS F31 CA239565NCI NIH HHS K99 CA201606NCI NIH HHS P50 CA098131NCI NIH HHS R35 CA197623NCI NIH HHS U01 CA195469NCI NIH HHS U54 CA193461NCI NIH HHS U54 CA209988
Abstract
Intratumor heterogeneity is postulated to cause therapeutic resistance. To prospectively assess the impact of HER2 (
Indexed as
AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoadjuvant TherapyTrastuzumabTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.